Latest From Dermira Inc.
US FDA not looking to reduce attendance at third-party patient meetings, which deliver 'bang for the buck.' Excessive sweating is first externally led PFDD meeting for a more common condition.
Third-quarter biopharma financing, which totaled $12.5 billion, was dominated by follow-on public offerings, which represented virtually half the value. Acquisition activity was headlined by a major move by Gilead in the CART market. Five alliances were signed worth over $1 billion, led by a partnership between two key players, Merck & Co. and AstraZeneca.
Following its partnership with Dicerna, the German pharma signs a second NASH deal with MiNA and inks three cancer-related transactions, including divestitures. Also, Amgen buys out Kirin’s half of their joint venture for $780m.
As it ends its pact with UCB, Dermira says it needs to focus on its own top assets and couldn't simultaneously launch Cimzia in psoriasis.
- Large Molecule
- Topical Delivery
- Specialty Pharmaceuticals
- Drug Delivery
- Therapeutic Areas
- Skintelligence Inc.
- North America
- Parent & Subsidiaries
- Dermira Inc.
- Senior Management
Thomas G Wiggans, CEO
Andrew Guggenhime , COO & CFO
Eugene A Bauer, MD, CMO
Chris Griffith, VP, Corp. Dev. & Strategy
Christine Conroy , SVP, Reg. Affairs
Hans Hofland, PhD, VP, Research & Nonclinical Dev.
Lori Lyons-Williams, Chief Commercial Officer
- Contact Info
Phone: (650) 421-7200
275 Middlefield Rd.
Menlo Park, CA 94025
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.